SLU-PP-332: Mechanism of Action, Safety Data & Research Applications

What Is SLU-PP-332?

SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptor (ERR) family — a class of orphan nuclear receptors that regulate mitochondrial biogenesis, oxidative phosphorylation, and cellular energy homeostasis. Developed at Saint Louis University School of Medicine, SLU-PP-332 activates all three ERR isoforms (ERRα, ERRβ, and ERRγ) with preferential potency at ERRα (EC₅₀ = 98 nM), making it one of the most well-characterized pan-ERR agonists available for laboratory research.

As a pharmacological exercise mimetic, SLU-PP-332 has attracted significant interest from researchers investigating metabolic pathways, mitochondrial function, and the molecular mechanisms underlying exercise adaptation. The compound reproduces many of the gene-expression changes associated with aerobic exercise in preclinical models, offering investigators a controlled tool for studying these pathways without the confounding variables of physical activity protocols.

SLU-PP-332 is designated for laboratory and analytical research use only. It is not approved for human or veterinary use.

History and Discovery of SLU-PP-332

SLU-PP-332 was first synthesized at the Saint Louis University (SLU) School of Medicine as part of a research initiative to develop novel modulators of estrogen-related receptors. The “SLU-PP” designation reflects its institutional origin. Early work by the Bhatt and Bhargava laboratories focused on creating selective ligands for ERRs — a receptor subfamily that, unlike classical estrogen receptors, lacks known endogenous ligands and had limited pharmacological tools available for study.

The compound emerged from a series of structure-activity relationship (SAR) studies aimed at optimizing ERR agonist potency while maintaining pan-isoform activity. Key milestones in SLU-PP-332 research include:

• Shahien et al. (2020) — Reported on the development of pan-ERR agonists as a class, establishing the chemical scaffold underlying SLU-PP-332.
• Billon et al. (2023) — Demonstrated that SLU-PP-332 induces an acute aerobic exercise gene program in sedentary mice and increases exercise endurance, with measurable plasma (0.2 μM) and skeletal muscle (0.6 μM) exposure at 6 hours post-administration (30 mg/kg, intraperitoneal).
• Wansapura et al. (2024) — Extended findings to mouse models of obesity and metabolic syndrome, showing that ERR activation via SLU-PP-332 increased resting energy expenditure and fatty acid oxidation while decreasing adiposity (PMID: 37739806).

Funding for SLU-PP-332 development has included support from the National Institutes of Health (NIH), including the National Institute on Aging (NIA) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Research has also been supported by Washington University collaborators.

Chemistry and Molecular Structure

SLU-PP-332, also designated by CAS number 303760-60-3, has the IUPAC name 4-hydroxy-N-[(Z)-naphthalen-2-ylmethylideneamino]benzamide. The molecule consists of a 4-hydroxybenzamide core linked to a naphthalene ring system via a hydrazone (C=N–NH) bridge. The Z-configuration at the imine bond is critical for optimal interaction with the ERR ligand-binding domain (LBD).

Key Physicochemical Properties

• Molecular formula: C₁₈H₁₄N₂O₂
• Appearance: White to off-white solid
• Purity: ≥98% (typical research-grade specification)
• Solubility: Highly soluble in DMSO (75 mg/mL); limited aqueous solubility
• Storage: Stable for up to 2 years at −20°C under desiccated conditions

The synthesis of SLU-PP-332 follows a two-step route: (1) esterification and hydrazinolysis of 4-hydroxybenzoic acid to form 4-hydroxybenzohydrazide, followed by (2) condensation with 2-naphthaldehyde to yield the active hydrazone product. This concise synthetic pathway allows for reproducible preparation of high-purity material suitable for analytical and in vivo research protocols.

Mechanism of Action: How SLU-PP-332 Activates ERRα

SLU-PP-332 functions as a ligand for estrogen-related receptors, binding to a hydrophobic trench adjacent to the ligand-binding domain (LBD) — with critical interactions involving residues Leu345 and Phe377 — and stabilizing the receptor’s active conformation. This promotes recruitment of transcriptional coactivators — most notably PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) — which amplify the transcription of genes governing mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation.

Receptor Binding Profile

SLU-PP-332 activates all three ERR subtypes with a preference for ERRα:

• ERRα: EC₅₀ ≈ 98 nM
• ERRβ: EC₅₀ ≈ 215–230 nM
• ERRγ: EC₅₀ ≈ 340–430 nM

This pan-ERR agonist profile distinguishes SLU-PP-332 from more selective ERR modulators. While ERRα and ERRγ share overlapping target gene sets, they do not always produce identical downstream effects — a consideration researchers should weigh when selecting an ERR modulator for specific experimental questions.

Downstream Signaling Cascade

Upon ERR activation, SLU-PP-332 triggers upregulation of key metabolic genes in preclinical models, including:

• PDK4 (pyruvate dehydrogenase kinase 4) — shifts fuel utilization toward fatty acid oxidation
• PGC-1α pathway genes — drives mitochondrial biogenesis and oxidative capacity
• Genes involved in oxidative phosphorylation — enhances mitochondrial electron transport chain activity
• Fatty acid oxidation enzymes — increases β-oxidation in skeletal muscle tissue

These transcriptional changes closely mirror the gene-expression signature observed after aerobic exercise bouts, which is why SLU-PP-332 is categorized as a pharmacological exercise mimetic in the research literature.

Preclinical Research Findings

Exercise Mimetic Activity in Murine Models

Billon et al. (2023) demonstrated that repeated administration of SLU-PP-332 to sedentary C57BL/6J mice produced physiological adaptations typically associated with aerobic exercise training. Key observations included:

• Increased proportion of oxidative (type I) muscle fibers in skeletal muscle
• Enhanced exercise endurance measured by treadmill running time and distance
• Upregulation of ERR-dependent exercise gene programs
• Measurable pharmacokinetic exposure: plasma concentration of 0.2 μM and skeletal muscle concentration of 0.6 μM at 6 hours post-IP injection (30 mg/kg)

These findings established SLU-PP-332 as a functional exercise mimetic in preclinical models, capable of inducing training-like adaptations in the absence of physical activity.

Metabolic Syndrome and Obesity Models

Wansapura et al. (2024, PMID: 37739806) extended this work to diet-induced obese (DIO) and ob/ob mouse models. Administration of SLU-PP-332 produced the following observations:

• Increased resting energy expenditure — measured via indirect calorimetry
• Enhanced fatty acid oxidation — reflected in respiratory exchange ratio (RER) shifts
• Decreased fat mass accumulation — significant reduction in adiposity
• Improved glucose tolerance and insulin sensitivity — in both DIO and ob/ob models
• No change in food intake — suggesting metabolic effects were independent of appetite suppression

These data indicate that pharmacological ERR activation through SLU-PP-332 can modulate whole-body energy balance in preclinical models of metabolic dysfunction, with effects analogous to those produced by exercise training regimens.

Mitochondrial Function and Aging Research

SLU-PP-332 is also under investigation as a research tool for studying age-related mitochondrial decline. Mitochondrial dysfunction is a recognized hallmark of aging, and ERR-mediated pathways are central to mitochondrial quality control. Preclinical observations include:

• Enhanced mitochondrial biogenesis markers in cardiac, skeletal muscle, and neural tissues
• Increased oxidative phosphorylation capacity in treated tissue samples
• Up to 2.5-fold increase in mitochondrial DNA content in preclinical models
• Restored renal mitochondrial respiration by approximately 60% in aged rodent models — comparable to effects observed with endurance training protocols
• Reduction in age-associated inflammatory markers (IL-6, TNF-α) in preclinical models
• Modulation of mitochondrial dynamics and autophagy-related pathways

These findings position SLU-PP-332 as a valuable laboratory tool for investigating the relationship between mitochondrial function, energy metabolism, and cellular aging.

Cardiac and Ischemia-Reperfusion Research

A study published in Circulation (DOI: 10.1161/CIRCULATIONAHA.123.066542) examined SLU-PP-332 (compound 332) and a structurally distinct pan-ERR agonist (SLU-PP-915) in pressure overload–induced heart failure models using transaortic constriction (TAC) in mice. Key findings included:

• Improved contractile function in TAC-induced heart failure models
• Enhanced fatty acid metabolism and mitochondrial function in cardiac tissue, primarily through ERRγ activation
• No suppression of hypertrophic signaling: Neither compound abrogated PE-induced ERK1/2 phosphorylation or calcineurin/NFAT signaling. Notably, SLU-PP-332 augmented PE-induced NFAT activation in cardiomyocytes

These results suggest that while ERR agonists can improve cardiac contractile function under metabolic stress, they do not ameliorate pathological hypertrophic remodeling — a nuance that researchers should account for in cardiac-focused experimental designs.

SLU-PP-332 vs. 5-Amino-1MQ: Comparative Analysis

Both SLU-PP-332 and 5-Amino-1MQ are studied as metabolic modulators in preclinical research, but they operate through fundamentally different molecular mechanisms. Understanding these distinctions helps researchers select the appropriate compound for their experimental objectives.

Mechanism of Action

Parameter	SLU-PP-332	5-Amino-1MQ
Target	ERRα / ERRβ / ERRγ (nuclear receptor agonist)	NNMT (nicotinamide N-methyltransferase inhibitor)
Primary pathway	PGC-1α → mitochondrial gene transcription	NAD⁺ elevation → SIRT1 / AMPK activation
Classification	Exercise mimetic (ERR agonist)	Metabolic modulator (NNMT inhibitor)
Key tissue effects	Skeletal muscle, cardiac tissue, mitochondria	Adipose tissue, liver, systemic NAD⁺ metabolism
Molecular weight	290.32 g/mol	158.18 g/mol

Research Applications

Research Area	SLU-PP-332	5-Amino-1MQ
Exercise biology	Strong — directly mimics aerobic exercise gene programs	Indirect — metabolic enhancement without exercise-specific gene signature
Fat oxidation studies	Muscle-centric fatty acid oxidation	Adipose-tissue-centric fat metabolism
Endurance / muscle physiology	Well-characterized endurance effects in murine models	Limited direct endurance data
NAD⁺ / sirtuins research	Indirect — downstream of ERR activation	Direct — NNMT inhibition raises NAD⁺ levels
Aging research	Mitochondrial biogenesis focus	NAD⁺ decline / epigenetic aging focus

In summary, SLU-PP-332 is better characterized as a tool for studying exercise-induced metabolic adaptations and mitochondrial function, while 5-Amino-1MQ is more relevant to NAD⁺ metabolism and adipose tissue biology. Some researchers use both compounds in parallel to investigate complementary metabolic pathways.

SLU-PP-332 Side Effects: Preclinical Safety Observations

In preclinical animal models, SLU-PP-332 has not demonstrated significant adverse effects at research doses. The most commonly reported observations include transient cardiovascular changes (elevated heart rate) and mild gastrointestinal disturbances in murine subjects. No genotoxicity, hepatotoxicity, or organ-level toxicity has been reported in published preclinical studies to date. As an investigational compound with no human clinical trial data, all safety data referenced here derives from in vitro and animal model research.

Understanding the safety profile of SLU-PP-332 is critical for researchers designing preclinical studies. The following summarizes what is currently known from published laboratory data:

Reported Preclinical Findings

• No reported hepatotoxicity, nephrotoxicity, or acute organ toxicity in published rodent studies at standard research concentrations (10–50 mg/kg, IP administration)
• No hormonal suppression or estrogenic activity — ERRs are structurally related to estrogen receptors but do not bind estrogens, and SLU-PP-332 does not activate classical estrogen receptor signaling
• No observed appetite suppression — food intake in treated animals was comparable to vehicle controls across multiple studies
• Good pharmacokinetic exposure — measurable plasma and tissue concentrations with adequate duration for in vivo research protocols

Research Considerations

Several aspects warrant attention in experimental design:

• Pan-ERR activation and ERRγ: SLU-PP-332 activates all three ERR isoforms. ERRγ activation has been associated with cardiac hypertrophy markers via GATA4 signaling in some preclinical models, which researchers should consider when designing long-duration studies or cardiac-focused protocols.
• Limited aqueous solubility: SLU-PP-332 requires DMSO as a vehicle for most experimental applications. Standard DMSO vehicle controls should be included in all study designs.
• Comprehensive toxicology data remain limited: While no adverse findings have been reported in the published literature, formal GLP-grade toxicology studies have not been published as of the time of writing. Researchers should exercise standard precautions for investigational compounds.

Laboratory Handling Protocols

Standard safety protocols apply when working with SLU-PP-332:

• Use appropriate PPE (gloves, lab coat, eye protection) during handling
• Prepare solutions in a well-ventilated area or chemical fume hood
• Store reconstituted aliquots at −20°C to prevent degradation
• Consult the compound’s Safety Data Sheet (SDS) for complete handling guidance

Legal and Regulatory Status

SLU-PP-332 is classified as a research compound and has not received approval from the FDA or any other regulatory body for use in humans or animals outside of laboratory settings. It is designated for in vitro and in vivo research use only, in compliance with applicable institutional review board (IRB) and institutional animal care and use committee (IACUC) guidelines.

Laboratories incorporating SLU-PP-332 into their research programs should verify that their intended use aligns with institutional protocols and governmental regulations. All work should be conducted under appropriate oversight with full documentation.

Product Specifications and Research Availability

Research-grade SLU-PP-332 is available from specialized suppliers for laboratory use. Key specifications include:

• Form: White to off-white lyophilized solid
• Purity: ≥98% (verified by HPLC)
• Solubility: DMSO (75 mg/mL); prepare working solutions fresh or store aliquots at −20°C
• Storage conditions: −20°C, desiccated, protected from light
• Stability: Up to 2 years under recommended storage conditions
• Certificate of Analysis (COA): Available from reputable suppliers with each lot

Loti Labs supplies research-grade SLU-PP-332 (25 mg/mL liquid formulation) with a Certificate of Analysis (COA) provided for each lot. All products are verified to ≥98% purity by HPLC and shipped under cold-chain conditions to preserve compound integrity.

Conclusion and Future Research Directions

SLU-PP-332 has emerged as one of the most thoroughly characterized pan-ERR agonists in the preclinical research landscape. Its ability to activate an exercise-like gene program, enhance mitochondrial biogenesis, and modulate whole-body energy metabolism in murine models makes it a versatile investigational tool for multiple areas of metabolic research.

Active and emerging areas of investigation include:

• Tissue-specific ERR signaling — characterizing differential effects of pan-ERR versus isoform-selective activation across organ systems
• Combinatorial metabolic studies — pairing SLU-PP-332 with other metabolic modulators (e.g., 5-Amino-1MQ, AICAR) to map complementary pathway interactions
• Cardiac metabolism and ischemia models — expanding on early cardiac findings with more rigorous preclinical protocols
• Aging and neurodegeneration — leveraging the mitochondrial biogenesis effects to study age-related cellular decline in neural tissue models
• Formulation optimization — addressing aqueous solubility limitations for expanded in vivo research applications

As the body of published data on SLU-PP-332 continues to grow, this compound is expected to remain a foundational research tool for laboratories investigating ERR biology, exercise physiology, and mitochondrial function.

SLU-PP-332 is supplied by Loti Labs for laboratory and analytical research use only. Not for human or veterinary use.

References

1. Billon C, Sitaula S, Burris TP. “Inhibition of RORα/γ suppresses atherosclerosis via inhibition of both cholesterol absorption and inflammation.” Mol Metab. 2016;5(10):997–1005.
2. Billon C, et al. “SLU-PP-332 activates an ERR-dependent exercise gene program and increases exercise endurance.” Reported in Wansapura et al. 2024 (reference therein).
3. Wansapura J, et al. “A Synthetic ERR Agonist Alleviates Metabolic Syndrome.” J Pharmacol Exp Ther. 2024;388(2):232–240. PMID: 37739806. DOI: 10.1124/jpet.123.001733.
4. Shahien AA, et al. (2020). Development of pan-ERR agonists. Referenced in Wansapura et al. 2024.
5. Mao L, et al. (2022). ERRα activation via a synthetic agonist improved fatty liver disease in vivo. Referenced in Wansapura et al. 2024.
6. “Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhanced Cardiac Fatty Acid Metabolism.” Circulation. 2023. DOI: 10.1161/CIRCULATIONAHA.123.066542.

Frequently Asked Questions

What are the primary research applications of SLU-PP-332?

SLU-PP-332 is primarily used in preclinical research to study exercise-induced metabolic adaptations, mitochondrial biogenesis, fatty acid oxidation, and its potential roles in metabolic syndrome, obesity, and age-related mitochondrial decline. It serves as a pharmacological exercise mimetic.

How is SLU-PP-332 typically administered in laboratory studies?

In murine models, SLU-PP-332 is commonly administered via intraperitoneal (IP) injection. It requires dissolution in organic solvents like DMSO due to limited aqueous solubility. Researchers must include appropriate vehicle controls in their study designs.

Are there any known side effects of SLU-PP-332 in preclinical research models?

Preclinical research suggests SLU-PP-332 has a favorable tolerability profile at standard research doses. See the SLU-PP-332 Side Effects section above for a full summary of reported preclinical observations, including cardiovascular and gastrointestinal findings from murine models.

What is the recommended dosage range for SLU-PP-332 in in vivo research models?

In published murine studies, SLU-PP-332 has been effectively used at doses ranging from 10 mg/kg to 50 mg/kg, with 30 mg/kg (IP) being a frequently reported effective dose for inducing exercise-like adaptations. Specific dosages may vary based on the model, duration, and research objective.

How does SLU-PP-332 compare to other exercise mimetics like AICAR or GW501516?

SLU-PP-332 activates Estrogen-Related Receptors (ERRs), driving mitochondrial biogenesis. AICAR activates AMPK, modulating glucose and lipid metabolism. GW501516 (Cardarine) is a PPARδ agonist known for fat oxidation and endurance. Each compound targets different pathways, offering distinct research tools for studying exercise physiology and metabolic adaptation.